Method for screening crystallization conditions in solution crystal growth

Information

  • Patent Grant
  • 7247490
  • Patent Number
    7,247,490
  • Date Filed
    Thursday, May 30, 2002
    21 years ago
  • Date Issued
    Tuesday, July 24, 2007
    16 years ago
Abstract
A method of screening protein crystal growth conditions with picogram to microgram amounts of protein in picoliter or nanoliter volumes is provided. A preferred method comprises a microarray with a plurality of micro-chambers in the microarray. A protein solution is placed into the micro-chambers by an automated dispensing mechanism. The protein crystal growth conditions of each of the micro-chambers is adjusted so that the protein crystal growth conditions in at least two of the micro-chambers differs. Crystallization of the protein solution in the micro-chambers is effected. Protein crystal growth in the micro-chambers is then observed.
Description
FIELD OF THE INVENTION

The present invention relates to the crystallization of proteins in or from protein solutions. The present invention particularly relates to a method of screening a large number of protein crystal growth conditions which may be conducive to protein crystallization. Even more particularly, the present invention relates to a method which identifies one or more optimum protein crystal growth conditions, while at the same time using substantially less protein solution.


BACKGROUND OF THE INVENTION

The crystallization of proteins for structure-function studies and structure based drug design has become an increasingly important part of biotechnology research. When crystal growth is attempted for a new protein, the appropriate chemical conditions (i.e. protein concentration in solution, precipitate type and concentration, pH, and growth temperature) are unknown and have typically been determined by trial and error experimentation.


Typically 1000 or more different sets of crystal growth conditions are screened to determine conditions conducive to crystallization. The screening involves repetitive procedures that are extremely laborious and tedious. With present laboratory protein crystal growth equipment, each crystallization chamber requires about one micro-liter of protein solution. The protein solutions typically have concentrations in the range of 10 to 25 micrograms per microliter to facilitate crystal growth. Therefore, to screen 1000 samples typically requires between 10 and 25 milligrams of protein. This is a considerable and costly amount, especially for proteins that are difficult to isolate or generally express. A large percentage (about 50%) of the proteins cannot easily be expressed in milligram quantities.


Thus, it would be desirable to provide methods for screening protein crystal growth conditions that require picogram to microgram amounts of protein for each screening condition. Preferably such methods would require only picogram to nanogram amounts of protein in picoliter to nanoliter volumes in each screening condition sample.


It would be further desirable to provide high throughput screening methods for screening protein crystal growth conditions in a large number of samples on a sub-microgram scale. These methods would use a microarray as a platform for protein crystal growth. The methods would also utilize automatic dispensing of solutions and scoring of crystal growth.


SUMMARY OF THE INVENTION

The present invention is a method of screening protein crystal growth conditions employing a minimal amount of protein, preferably on a picogram to microgram scale. Each screening sample has picogram to microgram amounts of protein in a picoliter to nanoliter volume. Predetermined protein crystal growth conditions are maintained and crystal growth is analyzed using both qualitative and quantitative criteria.


In a preferred embodiment, a microarray is provided for use in methods of screening protein crystal growth. Preferably the microarray has a plurality of micro-chambers in the microarray. The micro-chambers may be passive or a combination of passive micro-chambers that are connected with miniaturized active control elements such as, but not limited to, valves, pumps and electrodes. A protein solution is automatically dispensed into the micro-chambers. The protein crystal growth conditions of each of the micro-chambers is adjusted so that the protein crystal growth conditions of at least two of the micro-chambers differs. Protein crystal growth in the micro-chambers is then analyzed based on both the qualitative amount of crystallization and the quality of the crystals formed.


Additional objects, advantages, and features of the present invention will become apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

The various advantages of the present invention will become apparent to one skilled in the art by reading the following specification and subjoined claims and by referencing the following drawings in which:



FIG. 1 is a schematic illustrating a two well design in a microarray;



FIG. 2A is a schematic showing a top view of the placement of protein and precipitate solutions in a one well design;



FIG. 2B is a schematic showing a side view of placement of protein and precipitate solutions in a one well design;



FIG. 2C is a schematic showing a side view of an alternative placement of protein and precipitate solutions in one well;



FIG. 2D is a schematic showing a side view of placement of protein and precipitate solutions in two wells;



FIG. 2E is a schematic showing a top view of the placement of protein and precipitate solutions in a two well design;



FIG. 3 is a photograph showing a microarray; and



FIG. 4 is a photograph of a protein crystal obtained with nanogram amounts of protein in nanoliter volumes.





DETAILED DESCRIPTION OF INVENTION

The method of the present invention is for screening protein crystal growth conditions in protein solutions employing a minimal amount of protein in a minimal volume, preferably on a pico, nano or meso scale. Pico, nano or meso scale as used herein preferably employs (on average) picogram (pg), nanogram (ng) or microgram (μg) amounts of protein in picoliter (pl) or nanoliter (nl) volumes. Preferably, the amount of protein in each screening sample is less than about 5 μg. More preferably, the amount of protein in a screening sample will be less than about 1 μg. In one embodiment, the volume of protein solution in a screening sample is preferably from about 0.001 nl to about 250 nl and more preferably about 0.01 nl to about 10 nl. It will be appreciated by those skilled in the art that the volumes actually employed for any particular protein will be a function of (without limitation) the target protein and its concentration in the protein solution.


The protein solution contains one or more desired proteins for crystallization. As used herein, the term “protein” is meant to include all naturally occurring and synthetic peptides, polypeptides, proteins, and protein complexes. In one preferred embodiment the concentration of protein in the solution is from about 0.1 μg/μl to about 50 μg/μl, more preferably from about 0.1 μg/μl to about 10 μg/μl, and still more preferably about 0.1 μg/μl to about 1.0 μg/μl. In another preferred embodiment, the solution is buffered to a pH between about 2.0 and about 10.0, more preferably from about 3.0 to about 8.5. If desired, the protein solution may optionally contain agents that aid in solubilizing the protein at the desired protein concentration or conditions. For example, if the protein is a membrane protein, the protein solution may optionally contain one or more surface active agents, such as a detergent mixture. In one preferred embodiment, the protein solution also comprises components that assist in crystallization. By way of non-limiting example, the protein solution will comprise an aqueous salt solution, polyethylene glycol, or an alcohol. Such components as well as their selection, ranges, contraindications and the like are well known to those skilled in the art. See, for example, Gilliland, G. L. et al., Acta Crystallogr. D50:408-413 (1994); McPherson, A., Crystallization of Biological Molecules, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., pp. 487-524 (1999), expressly incorporated by reference.


The protein solution is dispensed onto a platform. The platform can be, by way of non-limiting example, a glass slide, a multi-well plate or a microarray. The solution is preferably dispensed using a device with picoliter or nanoliter accuracy. Preferably the dispensing device has at least a 90% accuracy on a picoliter or nanoliter scale. The protein solution can be dispensed manually using, for example, a syringe. In a highly preferred embodiment, automatic dispensing devices are used to dispense the protein solution.


A second solution, the reservoir or precipitate solution is provided. The precipitate solution is a solution that helps to bring about protein crystallization. It can comprise, for example, a salt solution, an alcohol or a polyethylene glycol. The second solution is provided either before, after, or simultaneously with the protein solution. The volume of the precipitate solution is typically equal to or greater than the volume of protein solution. The placement of the second solution is dependent on the crystallization method used but is typically in fluid communication with the first solution. Fluid communication can be liquid-liquid, liquid-vapor or vapor-vapor communication. Generally, a channel is provided for fluid communication. A channel is broadly defined herein as a space that enables fluid communication to occur. In the liquid-liquid diffusion method, the protein solution and precipitate solution contact each other at an interface. In batch crystallization, the two solutions are mixed together. If vapor diffusion crystallization is desired, the two solutions are kept separate but space is allowed for the diffusion of vapor between the solutions. Or, in an alternate embodiment, a single source or reservoir of the second solution may be employed. In yet another alternate embodiment, a desiccant source or a dry gaseous reservoir may be employed in place of the second solution. Specific conditions and variations in these methods are well known to the skilled artisan.


Protein crystal growth is monitored periodically, either qualitatively, quantitatively, or both. This may be by manual inspection using high resolution microscopy or electron microscopy. Preferably, protein crystal growth may be monitored automatically, by, for example, high resolution optical means which automatically detects crystal growth based on, for example, edge analysis. If desirable crystal growth is observed in a sample, the protein crystal growth conditions of that sample can be reproduced on a macro scale to produce a protein crystal for further analysis. Alternatively, if a precipitate or a clear sample is observed, these conditions can be used to optimize the conditions for additional screening. It will be appreciated that the platform must employ at least one path that is visually and/or optically clear to the method of detection.


In at least one preferred embodiment the method of the present invention for screening protein crystal growth employs a microarray with a plurality of wells or reservoirs as the platform. A microarray may be constructed, for example, similar to a micro-electromechanical chip. The microarray preferably has a planar shape and employs a size and thickness that are compatible with manual or automated plate grippers. The microarray can be made from different materials and by different techniques known to those skilled in the art. The material of the microarray that includes the wells or reservoirs is preferably minimally water absorbing, and is otherwise sufficiently unreactive with the components of the solution. This may be done as a laminate or provided as a coating, for example. Alternatively, a material that absorbs water at a predictable rate can also be used to construct the wells or reservoirs. The volumes of protein and precipitate solutions may then be adjusted to compensate for the water absorption of the material. Preferred materials include, but are not limited to, glass, fused silicon, quartz, a silicon wafer, a polymer or a polysulphone. Alternatively, the microarray can be made from a material coated with a hydrophobic material, such as polysulphone, to limit water absorption in the microarray. Alternatively, the microarray comprises more than one material. Preferably, the microarray is a composite with a bottom of thin glass plate bonded to plastic, glass, silicon rubber or other materials in which wells can be manufactured, with at least one side providing an optical path that is acceptable to the detection technique employed.


In an alternate embodiment, the surfaces of the wells are hydrophobic. For example, the material of the microarray may have a hydrophobic surface. Alternatively, the surfaces of the wells may be coated with a hydrophobic coating. Although not necessary, the hydrophobic surfaces of the wells prevent the drops of solutions from spreading.


The microarray includes a multitude of micron sized wells on the surface of the chip. The term wells encompasses wells, micro-chambers and any indentation sufficient of holding or retaining a desired volume of from about 0.001 nl to about 500 nl, preferably from about 0.01 nl to about 20 nl. The wells are spaced from each other on the surface. The precise number of wells on the surface of the microarray can vary, and the total number of wells on the surface is a matter of choice for the user.


Each of the wells has a volume sufficient to hold an amount of protein solution adequate for growing a protein crystal. Preferably, each of the wells holds a volume from about 0.001 nl to about 250 nl, preferably from about 0.01 nl to about 10 nl.


The wells of the microarray are made by using an etchant such as hydrogen fluoride or by other known etching or fabrication-techniques.


The wells can include known means for controlling conditions, individually or collectively, such as pressure, heating or cooling the wells, humidity levels in the wells as well as known means for stirring materials loaded into the wells.


In one arrangement, the wells of the microarray are not connected and separate from each other. In an alternative arrangement, adjacent wells of the microarray are connected by one or more channels which provide fluid communication between the adjacent wells (FIGS. 1 and 2D-E). Preferably, the connecting channels will have cross-section dimensions and length allowing control over the rate of transport of fluid, vapor, buffer, or precipitating or crystallizing agents through the channels. In one embodiment, varying the dimensions of the channels controls protein crystal growth condition. In an alternate embodiment, protein crystal growth conditions are controlled by placing a material in the micro-channels that controls fluid communication between the wells. Non-limiting examples are membranes, acrylamide or agarose. For example, the connecting micro-channels are from about 0.0001 to about 0.2 microns wide and from about 0.00005 to about 0.1 microns deep. Alternatively, the micro-channels are from about 0.0001 to about 2.0 microns wide and from about 0.00005 to about 0.5 microns deep. The micro-channels are formed in the microarray chip by the known etching techniques.


An example of two wells in a microarray (10) connected by a micro-channel is shown in FIG. 1. The protein solution well 12 is connected to precipitate solution well 14 by a microchannel 16. The dimensions of each well are designed to hold the desired amount of solution and may have the same or different dimensions. Initially, protein sample is dispensed into well 12 to an initial liquid height 18 and precipitate solution is dispensed into well 14 with liquid height 20. The top of the wells and microchannel are sealed by an optically clear cover 22. In vapor diffusion crystallization, the precipitate solution in well 14 has a lower vapor pressure than the protein solution in well 12, causing diffusion of solvent from well 12 to well 14 until the solution liquid height in well 12 reaches a final height 24. The concentration of the protein solution in well 12 precipitates protein crystal formation.


The microarray can also include a known means for transmitting a fluid or gas to the wells of the microarray from an external source. For example, an external mechanical pumping system marketed by Watson-Marlowe, Inc., under the trade designation “205U” can be used. The pumping system is a multi-channel cassette which delivers fluid or gas in reproducible and accurately controlled amounts. optionally, micro-valves are disposed in the wells and micro-channels to regulate the flow of fluid or vapor between the wells and through the micro-channels in a known manner.


An automated dispensing mechanism capable of accurately and/or repeatedly dispensing picoliter and/or nanoliter volumes is also provided. Preferably, the automated dispensing mechanism has an accuracy of at least about 90%. The automated dispensing mechanisms are preferably Piezo-based or fast solenoid dispensing mechanisms. More preferable, the dispensing mechanism is a fast solenoid dispensing mechanism. The dispenser has a large number of parallel capillaries. The capillaries are in fluid communication with a source of protein solution, a source of precipitate solution, and a source of buffer solution. The dispensing can be actuated by ultrasonic transducers that efficiently produce a pressure wave in the capillaries that contain the solutions. The dispenser is analogous to ink jet printer heads for computer printers but the fluid is not heated, thus not damaging the solutions.


The protein solution preferably comprises an aqueous protein solution at a concentration of from about 0.1 μg/μl to about 50 μg/μl. Preferably, the concentration is from about 0.1 μg/μl to about 10 μg/μl, more preferably from about 0.1 μg/μl to about 1.0 μg/μl. Preferably, the protein solution comprises a detergent mixture when crystallizing membrane proteins. The precipitate solution preferably comprises a concentrated aqueous salt solution or polyethylene glycol as precipitating agents. The buffer solution preferably has pH between about 2 and about 10.


The automated dispensing mechanism dispenses an initial volume of protein solution, an initial volume of precipitate solution, and an initial volume of buffer solution from the source of protein solution, the source of precipitate solution, and the source of buffer solution, respectively, into preselected wells or connecting channels of the microarray.


The placement of the initial volume of protein solution, the initial volume of precipitate solution, and the initial volume of buffer solution in the preselected wells or channels of the microarray is dependent upon the method utilized to effect crystallization of the protein in the protein solution.


Preferred methods to effect crystallization of the protein in the protein solution include liquid-liquid diffusion, batch diffusion, and vapor diffusion.


In the liquid-liquid diffusion method, the initial volume of protein solution is placed in one set of preselected wells, and the initial volume of precipitate solution is placed in a separate or different set of wells. The protein solution wells are connected to the precipitate solution wells by micro-channels. The initial volume of buffer solution may be placed in the micro-channels, or alternatively added directly to the initial volume of protein solution and/or precipitate solution.


The concentration, amounts, precipitate type, and pH of the initial volumes of protein solution, precipitate solution, and buffer solution are primary conditions which determine protein crystal growth in a protein solution. In preparing the initial solutions, and in the automated dispensing mechanism placement, these conditions and the sample placement are varied in accordance with a pre-designed program.


A cover plate is affixed to the microarray to convert the wells to micro-chambers and to convert the micro-channels to a capillary tube structure. The cover plate can made of the same or different material as the microarray, but the cover plate (or some portion of the well or chamber) must be transparent to permit optical analysis of the protein solutions in the chambers of the microarray. Preferably, the cover plate will be glass or other material that is visually or optically clear, such as an optically clear tape.


Alternatively, the environment surrounding the microarray can be controlled to limit evaporation of the solutions. Under controlled conditions of, for example, temperature and humidity, covering the samples may not be necessary.


The crystallizing agent in the precipitate solution, in selected micro-chambers, diffuses via the connecting capillaries to selected micro-chambers containing protein solution.


Protein crystal growth in the different chambers are then monitored by high resolution or other optical means which automatically detects crystal growth based on well known edge analysis. Alternatively, the protein crystal growth can be monitored by manual inspection using high resolution microscopy or electron microscopy. Preferably the protein crystal growth in the chambers is monitored by high resolution optical means which automatically detects crystal growth based on edge analysis.


Once crystal growth in a chamber is detected, that chamber's protein crystal growth conditions can be reproduced on a macro scale to produce a protein crystal which can be analyzed by x-ray crystallography. Alternatively, if a precipitate or clear sample is observed, the conditions in those samples can be used to optimize conditions for additional screening.


In the vapor diffusion method, the initial volume of protein solution is placed in one set of preselected wells, and the initial volume of precipitate solution is placed in a separate or different set of wells based on a pre-designed program, as with the liquid-liquid diffusion method (FIGS. 2D-E). The protein solution wells are connected to the precipitate solution wells by micro-channels. The initial volume of buffer solution is added to the initial volume of protein solution and/or initial volume of precipitate solution. Alternatively, the protein solution and precipitate solution can be placed in the same well such that the two solutions do not come into contact (FIGS. 2A-C).


As with liquid-liquid diffusion, the crystal growth is varied in different wells in accordance with a pre-designed program in which the placement, concentration, amounts, precipitate type, and pH conditions are varied in the different wells.


A cover plate is then affixed to the microarray as with the liquid-liquid diffusion method. The vapor pressure of the precipitate solution is lower than the vapor pressure of the protein solution. This causes the protein solution in a micro-chamber which is connected via a capillary to a micro-chamber containing a precipitate solution to evaporate and become super-saturated causing precipitation of protein. Crystal growth is monitored as in the liquid-liquid diffusion.


Alternatively, the protein solution is placed into wells of the microarray and the microarray is exposed to a single reservoir with the precipitate solution. This method allows for less fluid dispensing, but also less control of the protein crystal growth conditions with respect to each protein sample.


In the batch method, the volume of protein solution, the volume of precipitate solution, and the volume of buffer solution are placed together in individual wells of the microarray. In this method, the chip does not have connecting channels between the wells.


As with liquid-liquid diffusion and vapor diffusion methods, the crystal growth is varied in different wells in accordance with a pre-designed program in which the placement, concentration, amounts, precipitate type, and pH conditions are varied in the different wells.


As with liquid-liquid diffusion and vapor diffusion methods, a cover plate is affixed to the microarray, and the crystal growth is then monitored.


If desired, fluid or gas can delivered to the micro-chambers in reproducible and accurately controlled amounts from an external source by the external mechanical pumping system described above. Gas can also be delivered from the pressure generated by a standard glass bottle or tank. The fluid or gas delivered to the micro-chambers can be regulated by the micro-valves. The fluid or gas can be used to further alter the crystal growth conditions of the micro-chamber and increase the size of the protein crystals grown. These protein crystals can then be harvested and examined by x-ray crystallography or nuclear magnetic spectroscopy or other appropriate techniques.


Advantages of the present invention should now be apparent. The present invention provides a method of screening protein crystal growth conditions on a nano or meso scale. The method provides a means of screening protein crystal growth conditions for proteins that cannot be expressed in milligram quantities as well as those that can be expressed in larger quantities. Moreover, the substantial reduction in protein needed for the present invention reduces the costs associated with screening protein crystal growth conditions.


Also provided is an apparatus for screening crystal growth conditions. The apparatus comprises a microarray for the protein and precipitate solutions, an automatic dispensing mechanism for dispensing the solutions and an automated means for analyzing crystal growth.


The desired solutions, i.e., protein, precipitate and a buffer, are preferably automatically dispensed at a preset picoliter or nanoliter volume into the microarray by an automated dispensing mechanism. Preferably, the automatic dispensing mechanism dispenses discrete drops. Screening conditions such as the type of buffer and pH can be varied from sample to sample by programming the automatic dispenser. For example, arbitrary screens varying pH could be programmed by mixing the proper ratios using different drop counts from different stock solutions having different pH values. A pH range from 2.0 to 10.0 is then screened in steps of 0.2-0.5 pH units. Other conditions, such as crystallization agents and salt concentration are also controlled in a similar manner.


Mixing of the reagents can either be done before dispensing or after the solutions are dispensed into the microarray. Mixing in the microarray, for example, can be accomplished by ultrasonic mixing, high-speed dispensing of picoliter drops, rapid temperature fluctuation, or by static diffusion.


After mixing, preferably the wells of the microarray are sealed to control the microenvironment in the wells and to prevent evaporation of the solutions to dryness. More preferably, the wells are sealed with optically clear tape. Sealing the microarray involves an arm mounted on a YZ transverse mechanism. The X direction is along the plate transport direction. The arm, holding a roll of clear tape, moves past the last well in the row, drops to form positive vertical (Z axis) pressure, and then begins to move back in the negative Y direction while at the same time rotating the tape roll. Once the tape leaves the plate area, a guillotine mechanism shears the tape. The plate then moves in the X direction onto the next indexed row and the dispense process initializes again. Automated taping is reliably performed in many industries.


Protein crystal growth in the different wells is monitored by high resolution optical means which automatically detects crystal growth based on well known edge analysis. Such image acquisitions systems are commercially available.


The foregoing and other aspects of the invention may be better understood in connection with the following example, which is presented for purpose of illustration and not by way of limitation.


EXAMPLE 1

Nanoliter protein droplets were used for vapor diffusion, batch and liquid diffusion crystallization screening. The protein solutions of either lysozyme, thaumatin, or NAD synthetase were applied using a five microliter Hamilton syringe. To ensure complete wetting of the small droplet to the experiment chamber, the tip of the Hamilton syringe was placed in contact with the wall of each experiment chamber. A variety of microarrays were designed to accommodate protein solution droplets with volume ranges of 5-20 nanoliters and precipitate volumes of 100-200 nanoliters. The array prototyping was accomplished using MicroScope slides with permanent sealing of neoprene gaskets of varying thickness (0.1 mm 0.5 mm). Once all solutions were applied to an individual experiment chamber within the microscope slide, the experiment was sealed (with oil or grease) by placing a glass cover slide over the top of the gasket. FIG. 3 is a photograph of a typical design for a 60 chamber array prototype (gasket thickness=0.1 mm) and FIG. 4 is a photograph of crystals that were grown to 10 nanoliter protein droplets using a similar microarray slide.


A Cartesian robotic dispensing system was used to prepare crystallization solutions in a 6 by 10 experiment array. Five nanoliters of protein plus five nanoliters of precipitant were dispensed into one merged droplet in one depression in the experiment chamber (FIG. 3) and 50 nanoliters of precipitant plus 50 nanoliters of buffer were merged into one droplet in the connected depression. Thus, four solutions were dispensed for each experiment, and 6×10×4=240 total for the entire 6 by 10 array. Cartesian's instrument was able to dispense all of the solutions in less than 20 minutes. All external conditions used were known crystallization conditions for the particular proteins tested. The experiment was manually sealed and incubated at 22° C. for a period of one day. Crystals were observed in seventy percent of the droplets. While not wishing to be bound by theory, it is believed that the failure to observe crystals in 30% of the wells was due to inaccurate dispensing of the protein and precipitant five nanoliter drops in that the peizo tip did not position the drops together.


From the above description of the invention, those skilled in the art will perceive improvements, changes and modifications. Such improvements, changes and modifications within the skill of the art are intended to be covered by the appended claims.

Claims
  • 1. A method for determining crystallization conditions for a protein, the method comprising: delivering material to micro-chambers connected by micro-channels within a micro-array to form a plurality of different crystallization samples, the plurality of different crystallization samples comprising a protein to be crystallized and crystallization conditions which vary among the plurality of different crystallization samples;allowing crystals of the protein to form in the plurality of crystallization samples within the microfluidic device; and,identifying which of the plurality of crystallization samples within the microfluidic device comprise a precipitate or a crystal of the protein.
  • 2. A method for determining crystallization conditions for a protein, the method comprising: within a microfluidic device, delivering material to an enclosed microchamber via means for transmitting a fluid to the microchamber from an external source to form a plurality of different crystallization samples,the plurality of different crystallization samples comprising a protein to be crystallized and crystallization conditions which vary among the plurality of different crystallization samples;allowing crystals of the protein to form in the plurality of crystallization samples within the microfluidic device; and,identifying which of the plurality of crystallization samples within the microfluidic device comprise a precipitate or a crystal of the protein.
Parent Case Info

This application is a continuation of, and claims the benefit of, application Ser. No. 09/543,326, filed Apr. 5, 2000, abandoned, which is hereby incorporated herein in its entirety by references, and claims priority from U.S. application Ser. No. 60/128,018, filed Apr. 6, 1999.

US Referenced Citations (157)
Number Name Date Kind
3570515 Kinner Mar 1971 A
3747628 Holster et al. Jul 1973 A
4046159 Pegourie Sep 1977 A
4119368 Yamazaki Oct 1978 A
4153855 Feingold May 1979 A
4245673 Bouteille et al. Jan 1981 A
4263010 Randolph Apr 1981 A
4434704 Surjaatmadja Mar 1984 A
4517048 Shlichta May 1985 A
4668584 Uzgiris et al. May 1987 A
4755363 Fujita et al. Jul 1988 A
4833233 Carter May 1989 A
4886646 Carter et al. Dec 1989 A
4898582 Faste Feb 1990 A
4900147 Bowley et al. Feb 1990 A
4909933 Carter et al. Mar 1990 A
4919899 Herrmann et al. Apr 1990 A
4948564 Lyman et al. Aug 1990 A
5009861 Plaas-Link Apr 1991 A
5013531 Snyder et al. May 1991 A
5076698 Smith et al. Dec 1991 A
5078975 Rhodes et al. Jan 1992 A
5085562 Van Lintel Feb 1992 A
5088515 Kamen Feb 1992 A
5096388 Weinberg Mar 1992 A
5096676 McPherson et al. Mar 1992 A
5106592 Stapelmann et al. Apr 1992 A
5124935 Wallner et al. Jun 1992 A
5126115 Fujita et al. Jun 1992 A
5130105 Carter et al. Jul 1992 A
5164558 Huff et al. Nov 1992 A
5171132 Miyazaki et al. Dec 1992 A
5193685 Trevithick Mar 1993 A
5221410 Kushner et al. Jun 1993 A
5224843 Van Lintel Jul 1993 A
5256241 Noever Oct 1993 A
5259737 Kamisuki et al. Nov 1993 A
5265327 Faris et al. Nov 1993 A
5290240 Horres, Jr. Mar 1994 A
5336062 Richter Aug 1994 A
5346372 Naruse et al. Sep 1994 A
5362325 Shiraishi et al. Nov 1994 A
5375979 Trah Dec 1994 A
5376252 Ekstrom et al. Dec 1994 A
5400741 DeTitta et al. Mar 1995 A
5419278 Carter May 1995 A
5423287 Usami et al. Jun 1995 A
5529465 Zengerle et al. Jun 1996 A
5531185 Asano et al. Jul 1996 A
5544254 Hartley et al. Aug 1996 A
5581476 Osslund Dec 1996 A
5593130 Hansson et al. Jan 1997 A
5637469 Wilding et al. Jun 1997 A
5641681 Carter Jun 1997 A
5642015 Whitehead et al. Jun 1997 A
5643540 Carter et al. Jul 1997 A
5659171 Young et al. Aug 1997 A
5660370 Webster Aug 1997 A
5681024 Lisec et al. Oct 1997 A
5705018 Hartley Jan 1998 A
5716852 Yager et al. Feb 1998 A
5726404 Brody et al. Mar 1998 A
5728559 Nilsson et al. Mar 1998 A
5759014 Van Lintel Jun 1998 A
5775371 Pan et al. Jul 1998 A
5790421 Osslund Aug 1998 A
5836750 Cabuz Nov 1998 A
5842787 Kopf-Sill et al. Dec 1998 A
5855753 Trau et al. Jan 1999 A
5869604 Rousseau et al. Feb 1999 A
5872010 Karger et al. Feb 1999 A
5873394 Meltzer Feb 1999 A
5875817 Carter Mar 1999 A
5876187 Afromowitz et al. Mar 1999 A
5876675 Kennedy Mar 1999 A
5885470 Parce et al. Mar 1999 A
5922210 Brody et al. Jul 1999 A
5932100 Yager et al. Aug 1999 A
5932799 Moles Aug 1999 A
5942443 Parce et al. Aug 1999 A
5948684 Weigl et al. Sep 1999 A
5958694 Nikiforov Sep 1999 A
5961934 Arnowitz et al. Oct 1999 A
5964995 Nikiforov et al. Oct 1999 A
5971158 Yager et al. Oct 1999 A
5973779 Ansari et al. Oct 1999 A
5974867 Forster et al. Nov 1999 A
5985356 Schultz et al. Nov 1999 A
5997636 Gamarnik et al. Dec 1999 A
6007309 Hartley Dec 1999 A
6007775 Yager et al. Dec 1999 A
6031082 Nielsson et al. Feb 2000 A
6036920 Pantoliano et al. Mar 2000 A
6039804 Kim et al. Mar 2000 A
6043080 Lipshutz et al. Mar 2000 A
6057159 Lepre May 2000 A
6069934 Verman et al. May 2000 A
6110273 Sanjoh Aug 2000 A
6110986 Nozawa et al. Aug 2000 A
6117232 Sanjoh Sep 2000 A
6123769 Sanjoh Sep 2000 A
6129826 Nikiforov et al. Oct 2000 A
6134950 Forster et al. Oct 2000 A
6136272 Weigl et al. Oct 2000 A
6143248 Kellogg et al. Nov 2000 A
6155282 Zachary et al. Dec 2000 A
6156181 Parce et al. Dec 2000 A
6171865 Weigl et al. Jan 2001 B1
6174365 Sanjoh Jan 2001 B1
6174675 Chow et al. Jan 2001 B1
6186660 Kopf-Sill et al. Feb 2001 B1
6235175 Dubrow et al. May 2001 B1
6238538 Parce et al. May 2001 B1
6258331 Sanjoh Jul 2001 B1
6268158 Pantoliano et al. Jul 2001 B1
6291192 Pantoliano et al. Sep 2001 B1
6296673 Santarsiero et al. Oct 2001 B1
6296811 Sasaki Oct 2001 B1
6297021 Nienaber et al. Oct 2001 B1
6303322 Pantoliano et al. Oct 2001 B1
6319315 Sanjoh Nov 2001 B1
6368402 DeTitta et al. Apr 2002 B2
6387273 Abedi May 2002 B1
6402837 Shtrahman et al. Jun 2002 B1
6404849 Olson et al. Jun 2002 B1
6406903 Bray et al. Jun 2002 B2
6409832 Weigl et al. Jun 2002 B2
6413778 Carpenter et al. Jul 2002 B1
6417007 Gittleman et al. Jul 2002 B1
6423536 Jovanovich et al. Jul 2002 B1
6454945 Weigl et al. Sep 2002 B1
6468346 Arnowitz et al. Oct 2002 B2
6488896 Weigl et al. Dec 2002 B2
6630006 Santarsiero et al. Oct 2003 B2
6719840 David et al. Apr 2004 B2
6742661 Schulte et al. Jun 2004 B1
6743399 Weigl et al. Jun 2004 B1
20010016191 Osslund Aug 2001 A1
20010016314 Anderson et al. Aug 2001 A1
20010019845 Bienert et al. Sep 2001 A1
20010027745 Weigl et al. Oct 2001 A1
20010032582 DeTitta et al. Oct 2001 A1
20010055669 Schultz et al. Dec 2001 A1
20010055775 Schultz et al. Dec 2001 A1
20020022250 Hendrickson et al. Feb 2002 A1
20020029814 Unger et al. Mar 2002 A1
20020048610 Cima et al. Apr 2002 A1
20020054663 Olson et al. May 2002 A1
20020062783 Bray May 2002 A1
20020064485 Delucas et al. May 2002 A1
20020067800 Newman et al. Jun 2002 A1
20020164812 DeLucas et al. Nov 2002 A1
20030022383 DeLucas Jan 2003 A1
20030022384 DeLucas et al. Jan 2003 A1
20030027348 DeLucas et al. Feb 2003 A1
20030096421 DeLucas et al. May 2003 A1
20030180960 Consenza et al. Sep 2003 A1
Foreign Referenced Citations (29)
Number Date Country
779792 Jun 2005 AU
19631395 Feb 1998 DE
0 553539 Aug 1993 EP
592 094 Apr 1994 EP
703 364 Mar 1996 EP
706 004 Apr 1996 EP
779 436 Jun 1997 EP
0 815 940 Jan 1998 EP
829 360 Mar 1998 EP
845 603 Jun 1998 EP
999 055 Oct 2000 EP
2 155 152 Sep 1985 GB
2 308 460 Jun 1997 GB
02001013054 Jan 2001 JP
WO 9807069 Feb 1998 WO
WO 9900655 Jan 1999 WO
WO 9904361 Jan 1999 WO
WO 9917093 Apr 1999 WO
WO 9923284 May 1999 WO
WO 9952633 Oct 1999 WO
WO 0000678 Jan 2000 WO
WO 0043748 Jul 2000 WO
WO 0060345 Oct 2000 WO
WO 0060345 Oct 2000 WO
WO 0078445 Dec 2000 WO
WO 0109595 Feb 2001 WO
WO 0126797 Apr 2001 WO
WO 0192293 Dec 2001 WO
WO 03012430 Feb 2003 WO
Related Publications (1)
Number Date Country
20030022384 A1 Jan 2003 US
Provisional Applications (1)
Number Date Country
60128018 Apr 1999 US
Continuations (1)
Number Date Country
Parent 09543326 Apr 2000 US
Child 10161141 US